

## Interested in participating in a clinical research trial?

Scan QR code below to submit a form.



## Currently Enrolling Studies

### Amyotrophic Lateral Sclerosis (ALS)

- **233AS303** – A Phase 3 Randomized, Placebo-Controlled Trial with a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults with a Confirmed Superoxide Dismutase 1 Mutation. [NCT04856982](#)
- **PrecisionMed Protocol 4800** – A single or multiple visit protocol for collection of DNA/RNA/SERUM/PLASMA/CSF in Amyotrophic Lateral Sclerosis and related disorders.

### Becker Muscular Dystrophy

- **EDG-5506-201** - A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy.” [NCT05291091](#)

### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- **80202135CDP3001** – Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). [NCT05327114](#)
- **IMVT-1401-2401** – A Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with active CIDP. [NCT05581199](#)

### Dermatomyositis

- **PVT-2201-301** – A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis (VALOR). [NCT05437263](#)
- **MS200569\_0041** - A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care. [NCT05650567](#)

## Interested in participating in a clinical research trial?

Scan QR code below to submit a form.



## Currently Enrolling Studies

### Idiopathic Inflammatory Myopathy

- **ARGX-113-2007** – A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy. [NCT05523167](https://clinicaltrials.gov/ct2/show/study/NCT05523167)

### Inclusion Body Myositis

- **ABC008-IBM-201** - A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis. [NCT05721573](https://clinicaltrials.gov/ct2/show/study/NCT05721573)

### Myasthenia Gravis

- **R3918-MG-2018** – Efficacy And Safety Of Pozelimab And Cemdisiran Combination Therapy In Patients With Symptomatic Generalized Myasthenia Gravis. [NCT05070858](https://clinicaltrials.gov/ct2/show/study/NCT05070858)
- **IMVT – 1401-3101** – A Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis. [NCT05403541](https://clinicaltrials.gov/ct2/show/study/NCT05403541)

### Myotonic Dystrophy Type 1

- **VX22-MDO-801**- A Study to Assess Video Hand Opening Time and Ambulation in Healthy Volunteers and Individuals with Myotonic Dystrophy Type 1